Saniona publishes its interim report for the third quarter of 2024
| Three Months Ended September 30, 2024 (2023) | Nine Months Ended September 30, 2024 (2023) |
| Revenue was SEK 7.2 M (5.5 M) | Revenue was SEK 21.3 M (11.5 M) |
| Operating profit/loss was SEK -18.9 M (-18.4 M) | Operating profit/loss was SEK -48.5 M (-61.3 M) |
| Net profit/loss was SEK -29.5 M (-24.1 M) | Net profit/loss was SEK -58.4 M (-67.1 M) |
| Cash and cash equivalent SEK 41.3 M (49.3) | Cash and cash equivalent SEK 41.3 M (49.3) |
| Basic earnings/loss per share was SEK -0.26 (-0.38) | Basic earnings/loss per share was SEK -0.53 (-1.05) |
| Diluted earnings/loss per share were SEK -0.26 (-0.38) | Diluted earnings/loss per share were SEK -0.53 (-1.05) |
Business highlights in Q3 2024
- September 18, Saniona receives regulatory approval for SAN711 Biomarker Study.
Significant events after the reporting period
- October 1, Saniona provides update on major progress for SAN2355. The company has identified a stable solid form of the substance and completed the synthesis optimization.
- October 7, Saniona initiates SAN711 Biomarker study.
- October 14, Saniona Ion Channel Research Collaborations with Boehringer Ingelheim Reaches Milestone, resulting in a research milestone payment of €500,000 (approximately SEK 5.7 million).
- October 23, Fenja Capital II A/S (previously Formue Nord Fokus A/S) requested conversion of outstanding convertibles for a total nominal amount of SEK 2 million.
- November 6, Saniona’s partner, Productus Medix, did not receive approval from Mexican regulatory agency (COFEPRIS) for tesofensine for obesity. Medix is entering a dialogue with the agency regarding the path forward as it appears that the decision by COFEPRIS has not been based on the full data package submitted by Medix.
- November 12, Saniona comments on Medix’s recent regulatory submission for tesofensine in obesity.
- November 26, Saniona Announces Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases.
Comments from the CEO
“The deal with Acadia Pharmaceuticals is transformational for Saniona, as it validates our R&D approach, secures progress of one of our lead assets, and provides a strong cash position allowing us to bring several pipeline assets to key value-inflection points over the next years”.